168 related articles for article (PubMed ID: 28612749)
1. Liver Biopsy in Chronic Liver Diseases: Is There a Favorable Benefit: Risk Balance?
Larrey D; Meunier L; Ursic-Bedoya J
Ann Hepatol; 2017; 16(4):487-489. PubMed ID: 28612749
[TBL] [Abstract][Full Text] [Related]
2. Natural History of Patients Presenting with Autoimmune Hepatitis and Coincident Nonalcoholic Fatty Liver Disease.
De Luca-Johnson J; Wangensteen KJ; Hanson J; Krawitt E; Wilcox R
Dig Dis Sci; 2016 Sep; 61(9):2710-20. PubMed ID: 27262844
[TBL] [Abstract][Full Text] [Related]
3. [Chronic hepatitis C--clinical course and genotypical pattern of distribution in patients of a Berlin infection clinic].
Baumgarten R; Fengler JD; Roschke I; Schreier E
Z Arztl Fortbild (Jena); 1994 Oct; 88(10):793-6. PubMed ID: 7825360
[No Abstract] [Full Text] [Related]
4. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.
Haga Y; Kanda T; Sasaki R; Nakamura M; Nakamoto S; Yokosuka O
World J Gastroenterol; 2015 Dec; 21(46):12989-95. PubMed ID: 26675364
[TBL] [Abstract][Full Text] [Related]
6. Epidemiological assessment of liver disease in northeastern Brazil by means of a standardized liver biopsy protocol.
Lembrança L; Medina J; Portugal M; Almeida D; Solla J; Gadelha R; de Freitas LA; Paraná R
Ann Hepatol; 2011; 10(1):43-9. PubMed ID: 21301009
[TBL] [Abstract][Full Text] [Related]
7. How to Approach a Patient With Nonalcoholic Fatty Liver Disease.
Tilg H
Gastroenterology; 2017 Aug; 153(2):345-349. PubMed ID: 28647352
[No Abstract] [Full Text] [Related]
8. [Diagnosis of chronic hepatitis].
Kuhn R; Rambach W; Kalk JF; Klein CP
Dtsch Med Wochenschr; 1998 Sep; 123(36):1056-7. PubMed ID: 9765611
[No Abstract] [Full Text] [Related]
9. Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease.
Weyler J; Verrijken A; Hornemann T; Vonghia L; Dirinck E; von Eckardstein A; Vanwolleghem T; Michielsen P; Peiffer F; Driessen A; Hubens G; Staels B; Francque S; Van Gaal L
Acta Diabetol; 2021 Mar; 58(3):319-327. PubMed ID: 33084982
[TBL] [Abstract][Full Text] [Related]
10. Is cryptogenic cirrhosis different from NASH cirrhosis?
Thuluvath PJ; Kantsevoy S; Thuluvath AJ; Savva Y
J Hepatol; 2018 Mar; 68(3):519-525. PubMed ID: 29162389
[TBL] [Abstract][Full Text] [Related]
11. A Comparison of Brunt's Criteria, the Non-Alcoholic Fatty Liver Disease Activity Score (NAS), and a Proposed NAS Scoring that Includes Fibrosis in Non-Alcoholic Fatty Liver Disease Staging.
Santiago-Rolón A; Purcell D; Rosado K; Toro DH
P R Health Sci J; 2015 Dec; 34(4):189-94. PubMed ID: 26602577
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune Hepatitis Leading to Liver Cirrhosis: A Case Report.
Shrestha M; Subedi SC; Shah S; Acharya J; Regmi M; Mehta N
JNMA J Nepal Med Assoc; 2022 Dec; 60(256):1059-1062. PubMed ID: 36705108
[TBL] [Abstract][Full Text] [Related]
13. Settling the Score: Which Fibrosis Screening Tool Is the Most Reliable for Nonalcoholic Fatty Liver Disease?
Bou Daher H; Manka P; Syn WK
Dig Dis Sci; 2023 Jun; 68(6):2217-2220. PubMed ID: 36947290
[No Abstract] [Full Text] [Related]
14. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients.
Mathiesen UL; Franzén LE; Frydén A; Foberg U; Bodemar G
Scand J Gastroenterol; 1999 Jan; 34(1):85-91. PubMed ID: 10048738
[TBL] [Abstract][Full Text] [Related]
15. Non-invasive fibrosis assessment in non-alcoholic fatty liver disease.
Rios RS; Zheng KI; Targher G; Byrne CD; Zheng MH
Chin Med J (Engl); 2020 Nov; 133(22):2743-2745. PubMed ID: 32932282
[No Abstract] [Full Text] [Related]
16. Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases.
Ginès P; Castera L; Lammert F; Graupera I; Serra-Burriel M; Allen AM; Wong VW; Hartmann P; Thiele M; Caballeria L; de Knegt RJ; Grgurevic I; Augustin S; Tsochatzis EA; Schattenberg JM; Guha IN; Martini A; Morillas RM; Garcia-Retortillo M; de Koning HJ; Fabrellas N; Pich J; Ma AT; Diaz MA; Roulot D; Newsome PN; Manns M; Kamath PS; Krag A;
Hepatology; 2022 Jan; 75(1):219-228. PubMed ID: 34537988
[TBL] [Abstract][Full Text] [Related]
17. The role of neutrophil to lymphocyte ratio for the assessment of liver fibrosis and cirrhosis: a systematic review.
Peng Y; Li Y; He Y; Wei Q; Xie Q; Zhang L; Xia Y; Zhou X; Zhang L; Feng X; Chen K; Chen S; Chen W; Long Q; Chai J
Expert Rev Gastroenterol Hepatol; 2018 May; 12(5):503-513. PubMed ID: 29629626
[TBL] [Abstract][Full Text] [Related]
18. Acute presentation of autoimmune hepatitis: a multicentre study with detailed histological evaluation in a large cohort of patients.
Nguyen Canh H; Harada K; Ouchi H; Sato Y; Tsuneyama K; Kage M; Nakano M; Yoshizawa K; Takahashi A; Abe M; Kang JH; Koike K; Inui A; Fujisawa T; Takaki A; Arinaga-Hino T; Torimura T; Suzuki Y; Fujiwara K; Zeniya M; Ohira H; Tanaka A; Takikawa H;
J Clin Pathol; 2017 Nov; 70(11):961-969. PubMed ID: 28428284
[TBL] [Abstract][Full Text] [Related]
19. Improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis B and nonalcoholic fatty liver disease.
Xu N; Xie Q; Li J; Gao Y; Li X
J Int Med Res; 2020 Feb; 48(2):300060520903667. PubMed ID: 32070159
[TBL] [Abstract][Full Text] [Related]
20. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.
Poynard T; Bedossa P; Opolon P
Lancet; 1997 Mar; 349(9055):825-32. PubMed ID: 9121257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
